AI-supported colorectal polyp detectionStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 27 June 2024Expected publication date: 25 September 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024